FinancialsNasdaq
Institutional-grade research for retail investors
SEC EDGAR: CIK 2019505HIT stock profile & AI dashboard →

13F Pro Quality Score

27.4/100

Rank #2,470 of 2,879 stocks

View Financials peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

4.8/100

Profitability

37.6/100

Balance Sheet

36.0/100

Earnings Quality

30.0/100

Free Cash Flow

29.6/100

Institutional Flow

97.7/100

Revenue Scale

8.7/100

Dilution Risk

26.8/100

HIT Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Health In Tech, Inc. (HIT), a Financials sector company. 13F Pro's AI-powered ranking engine scores HIT at 27.4/100 on a 32-signal composite quality model, placing it at rank #2,470 of 2,879 stocks — the bottom half of the AI-ranked universe. HIT scores in the top quartile across institutional flow (97.7). Areas of concern include revenue growth (4.8) and revenue scale (8.7), which score below median versus the broader universe. Shareholder dilution risk is elevated at 26.8/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Health In Tech, Inc. reports quarterly revenue of $8.8M, net income of $-1.6M, free cash flow of $-3.3M. Top institutional holders of HIT by reported 13-F value include Mink Brook Asset Management, VANGUARD CAPITAL MANAGEMENT, HEIGHTS CAPITAL MANAGEMENT,, based on the most recent SEC filings. HIT trades on the Nasdaq exchange and files with the SEC under CIK 2019505. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate HIT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Health In Tech, Inc. directly from SEC EDGAR.

Revenue

Q1 2026

$8.8M

Net Income

Q1 2026

$-1.6M

Free Cash Flow

Q1 2026

$-3.3M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+71.0% YoY
$33.3MFY 2025
FY22 FY23 $19.2MFY24 $19.5MFY25 $33.3M

Net Income

+90.7% YoY
$1.3MFY 2025
FY22 FY23 FY24 $670.5KFY25 $1.3M

EPS (Diluted)

+100.0% YoY
$0.02FY 2025
FY22 FY23 FY24 $0.01FY25 $0.02

Total Assets

+46.4% YoY
$23.1MFY 2025
FY22 FY23 $11.5MFY24 $15.8MFY25 $23.1M

Op. Cash Flow

+44.0% YoY
$3.1MFY 2025
FY22 FY23 $1.5MFY24 $2.2MFY25 $3.1M

AI Insight: HIT Ratio Trends

Health In Tech's profitability collapsed across all metrics in Q1 2026, with operating margin plunging to -23.6% from -5.9% in Q4 2025.

Operating margin deteriorated from 8.9% in Q2 2025 to -23.6% in Q1 2026, signaling severe operational distress.

ROIC swung sharply negative to -38.3% in Q1 2026 from positive 20.3% in Q2 2025, destroying shareholder value.

TTM net profit margin of -2.4% reflects mounting losses over the trailing twelve months.

Quarterly deterioration accelerated Q4 2025 into Q1 2026; investigate whether Q1 represents a bottom or ongoing decline.

All profitability and return metrics now deeply negative; capital structure risks (D/E unavailable) and cash burn require urgent clarification.

Get alerted when HIT's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Health In Tech, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)
XBRL financial facts (revenue, EPS, margins)
Insider transactions (Form 4)
Institutional 13F holdings
Quality rankings (32 signals)
AI analyst debates & daily meetings
Historical financial trends
Peer comparison & sector analysis

Top Institutional Holders of HIT

Put HIT on your watchlist

Track score changes the day Health In Tech, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Is HIT a good stock to buy?

13F Pro's AI-powered analysis of Health In Tech, Inc. (HIT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Financials sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for HIT are available on the HIT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own HIT?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling HIT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Health In Tech, Inc.'s investment landscape.